It should be emphasized that an inhibitor (DFMO) of the polyamine biosynthesis enzyme ODC1 has been approved by the US FDA for facial hirsutism treatment, and preclinical data characterized DFMO as a potential tumor prevention reagent (Alexiou et al., 2017). The gene discussed is ODC1; the disease is neoplasm.